Withdrawal of cerivastatin from the world market
AUTOR(ES)
Furberg, Curt D
FONTE
BioMed Central
RESUMO
Cerivastatin was recently withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure. The risk was found to be higher among patients who received the full dose (0.8 mg/day) and those who received gemfibrozil concomitantly. Rhabdomyolysis was 10 times more common with cerivastatin than the other five approved statins. We address three important questions raised by this withdrawal. Should we continue to approve drugs on surrogate efficacy? Are all statins interchangeable? Do the benefits outweigh the risks of statins? We conclude that decisions regarding the use of drugs should be based on direct evidence from long-term clinical outcome trials.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=59524Documentos Relacionados
- Bayer pulls cerivastatin (Baycol) from market
- The world of the market place
- The world market for soybeans: price transmission into Brazil and effects from the timing of crop and trade
- Smoke free hospitals: Withdrawal from cigarettes should not be confused with withdrawal from nicotine
- From around the world